A study compared effectiveness of intermittent montelukast with placebo in reducing wheezing episodes in 1358 children aged 10 months to 5 years and whether genotype determined the patient outcome. Study authors found that intermittent montelukast only reduced wheezing episodes in children with arachidonate 5-lipoxygenase (ALOX5) gene promoter 5/5, a gene that has previously been associated with a better response to montelukast in adults. There was no correlation ...Tuesday 9 September 2014
The Lancet Respiratory Medicine: Intermittent Montelukast in Children Aged 10 Months to 5 Years With Wheeze (WAIT Trial)
A study compared effectiveness of intermittent montelukast with placebo in reducing wheezing episodes in 1358 children aged 10 months to 5 years and whether genotype determined the patient outcome. Study authors found that intermittent montelukast only reduced wheezing episodes in children with arachidonate 5-lipoxygenase (ALOX5) gene promoter 5/5, a gene that has previously been associated with a better response to montelukast in adults. There was no correlation ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment